

PROC. SOC. EXP. BIOL. AND MED., 1948, v69, 279.

4. Dubé, F., *Science*, 1952, v116, 278.

5. Von Euler, H., *Kem Arb.*, 1947, Ny följd II, v9.

6. Wright, J. M., *Ann. Bot.*, 1951, v15, 493.

7. De Ropp, R. S., *Nature*, 1948, v162, 459.

8. Ziebur, N. K., personal communication.

9. Loo, T., and Tang, Y., *Am. J. Bot.*, 1945, v32, 106.

10. Bonner, J., *Ibid.*, 1949, v36, 323.

Received December 14, 1953. P.S.E.B.M., 1954, v85.

An Antihemolytic Action of Pyridoxal.* (20890)

PAUL N. SELBY, JR., HALVOR N. CHRISTENSEN, AND THOMAS R. RIGGS.

From the Department of Biochemistry and Nutrition, Tufts College Medical School, Boston.

In studying the action of pyridoxal on the concentrative uptake of amino acids by the Ehrlich mouse-ascites tumor cell, an anti-hemolytic action toward the contaminating red blood cells was accidentally noted. The cause of the spontaneous hemolysis in the ascitic fluid *in vitro* is unknown, but samples to which mM pyridoxal had been added escaped red cell breakage. Although we have not been able to demonstrate at will a protective action of pyridoxal at this level, an antihemolytic action can readily be shown at a 10 mM level.

Method. The procedure used was much like that of Wilbrandt(1). Blood was taken by venipuncture from persons in the post-absorptive state, and the blood treated with heparin. Aliquot portions were added to 2 samples of 10 volumes of the medium of Raker *et al.*(2). In one of the 2 portions of medium 10 mM per L of pyridoxal, or of sodium indoleacetate, replaced 5 or 10 mM per L of sodium chloride, respectively; in this way the osmotic pressure was kept uniform. The suspensions were then shaken for one hour at 37°C in an atmosphere of 95% oxygen and 5% carbon dioxide. Aliquot portions were then added with stirring to 10 to 20 volumes of hypotonic sodium chloride, buffered at pH 7.4 with 15 mM sodium phosphate. The suspensions were stirred occasionally for an hour, then centrifuged and the extent of hemolysis determined by measuring

spectrophotometrically the optical density of the supernatant hemoglobin solutions. The time intervals were not critical; the same results were obtained after 15 minutes of exposure to hypotonicity. In calculating the osmolarities of the hypotonic solutions account was taken of the volume of the Raker medium and plasma included in the mixture.

Results and discussion. The results are illustrated in Fig. 1. The shift of the position of the curve was by 5 to 10 milliosmoles per liter. This effect would be expected if pyridoxal caused a displacement of cell solutes or a shrinkage of the cells. With the carcinoma cells of the Ehrlich ascites tumor, pyridoxal causes large amounts of potassium to move out of the cells; this shift is partially compensated by chloride exodus, and partially by sodium entrance into the cells(3). The




FIG. 1. Antihemolytic action of 10 mM pyridoxal (A and B) and indoleacetate (C). The encircled points represent the degree of hemolysis when the chemical agent was present, the crosses, when it was absent.

* This investigation was supported in part by grants from The National Cancer Institute, National Institutes of Health, U. S. Public Health Service, and the Abbott Laboratories, Inc.

cells shrink considerably. Erythrocytes show a similar but smaller shift both of electrolytes and water.

Indoleacetic acid also causes shrinkage of the tumor cells, and loss of potassium chloride. With erythrocytes the effect was quite small, although definite shrinking was seen(3). In correspondence the indoleacetate ion showed a smaller effect than pyridoxal in the present experiments (Fig. 1).

Evidence obtained with tumor cells from pyridoxine-deficient mice implicates pyridoxal in the normal process of amino acid accumulation by these cells(3,4). A close relationship to the transfer of potassium into cells is also indicated(3).

Summary. Pretreatment of erythrocytes

with 10 mM pyridoxal makes the cells subsequently more resistant to lysis by hypotonic solutions. Indoleacetic acid shows the same behavior to a smaller degree. These effects are attributed to a net loss of cell solutes in the form of potassium and chloride which the agents produce.

1. Wilbrandt, W., *Arch. ges. Physiol.*, 1941, v245, 22.
2. Raker, J. W., Taylor, I. M., Weller, J. M., and Hastings, A. B., *J. Gen. Physiol.*, 1950, v33, 691.
3. Christensen, H. N., Riggs, T. R., and Coyne, B., mss. in preparation.
4. Riggs, T. R., Coyne, B., and Christensen, H. N., *Biochim. Biophys. Acta*, 1953, v11, 303.

Received December 23, 1953. P.S.E.B.M., 1954, v85.

Effect of Isoniazid on Vitamin B₆ Metabolism; Its Possible Significance in Producing Isoniazid Neuritis.* (20891)

J. PARK BIEHL[†] AND RICHARD W. VILTER. (Introduced by L. H. Schmidt.)
(With the technical assistance of Florence C. Beall and Cora Ellen Kennedy.)

From the Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati.

Peripheral neuritis occurs as a side-effect of isoniazid (isonicotinic acid hydrazide, INH) therapy in tuberculosis, particularly when large doses are employed(1-6). This usually consists of paresthesia and numbness of the fingers and toes, advancing centripetally, with muscle soreness and weakness in some cases if medication is not discontinued. Vibratory sense may be impaired, and patchy hypesthesia has been seen. Reflexes may be diminished or exaggerated. The symptoms usually disappear within a few weeks if INH is promptly discontinued at the onset; however, late residuals such as burning feet, atrophy, fasciculation, and paresthesia may persist for months. In our experience, using a dose of 20 mg/kg/day of INH, neuritis has appeared in a predictable percentage of patients within definable limits of time. The similarity of this side effect to the neuritis

induced by the vit. B₆ antagonist, desoxypyridoxine(7), has led us to investigate vit. B₆ metabolism in patients who were receiving INH for tuberculosis. The data to be reported indicate that INH does interfere with B₆ metabolism, and that the neuritis may be prevented with large doses of B₆.

Materials and methods. Subjects. All subjects studied were adult patients with active tuberculosis either on the wards of the Cincinnati General Hospital, or at Dunham Hospital, Cincinnati. During the study, all were receiving streptomycin (SM), one g daily or twice weekly. All patients were given the regular hospital diet. The various aspects of the study were carried out concurrently. Leading questions concerning symptoms of neuritis were avoided in evaluating the course of the patients, in order to eliminate the factor of suggestion. Any remarks by the patient, on the other hand, possibly connected with the onset of neuritis were pursued carefully. Neurologic testing was performed, but served no useful purpose in detecting the onset of neuritis. **Incidence of**

* This work supported by grants from the Trustees of Dunham Hospital, Cincinnati, the National Tuberculosis Association, and the National Vitamin Foundation.

[†] Teaching Fellow, American Trudeau Society.